Exclusive Summary

• - Core patents/data exclusivity for IR tablets expired long ago; 150/300/600 mg are mainstream SKUs enabling rapid substitution and tender access globally.
• - Targets the ~50 million people with epilepsy worldwide, with ~60% focal-onset patients; broad adult and pediatric applicability meets substantial unmet need.
• - Endorsed by major guidelines (e.g., NICE, AAN/AES, ILAE) as first-line or preferred alternative for focal epilepsy with fewer interactions and better tolerability than carbamazepine.
• - Market is fully genericized with many players, but EU-27 approvals provide quality credibility and faster multi-country market access.
• - Typically achieves 70–90% price erosion versus originator, and full strength range supports dose optimization and cost control across hospital, payer, and retail channels.